Admedus announces Canadian CardioCel launch

/in /by

THE ROADHOUSE PHARMACY: Admedus Limited (ASX: AHZ) has been granted a Medical Device Licence in Canada by Health Canada for the company’s CardioCel®.

CardioCel is the Admedus Group’s lead regenerative tissue bio-implant and is used in repairing heart defects, including the repair of heart valves.

Canada becomes the latest market approval for CardioCel, with the product already having received CE Mark in Europe and 510k clearance in the United States.

The product’s use in Australia continues under the early access Authorised
Prescriber Scheme (APS).

Admedus said CardioCel is being used by heart surgeons to treat patients at centres across Australia, Europe and the US.

“The Canadian approval is another important step in the global launch of CardioCel and will add revenue growth for the Admedus Group,” Admedus chief executive officer Lee Rodne said in the company’s announcement to the Australian Securities Exchange.

The company explained the launch of CardioCel in Canada is part of a continuing global strategy to gain product regulatory approval in major markets and directly secure key centres and surgeons as customers.

CardioCel is now available for immediate sale and use by heart surgeons throughout Canada.

Email: info.au@admedus.com

Website: www.admedus.com